Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 5/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081636 | 1.00 | GPR52 (0.54) | GPR52NPC1RAB9AMEN1KMT2A | |
| SCHEMBL946754 | 0.83 | NPC1 (0.50) | GPR52NPC1RAB9AMEN1KMT2A | |
| SCHEMBL29000605 | 0.81 | MEN1 (0.58) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL29926850 | 0.81 | MEN1 (0.58) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL28281740 | 0.80 | NPC1 (0.62) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL2660767 | 0.77 | MEN1 (0.58) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL30379649 | 0.77 | MEN1 (0.58) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL2660769 | 0.77 | MEN1 (0.58) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL8200615 | 0.76 | NPC1 (0.47) | GPR52NPC1RAB9AMEN1KMT2A | |
| SCHEMBL4387560 | 0.76 | EGFR (0.39) | GPR52EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036457-A1 | Utilities of olefin derivatives | YAMAMORI TERUO | 2009-02-05 | — | — | US | disclosed |
| US-20040242615-A1 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242615-A1 | Utilities of olefin derivatives | APOL1, NR1H2, APOB | GPR52 974/4885NPC1 19/4885RAB9A 4723/4885 |
| US-20090036457-A1 | Utilities of olefin derivatives | APOL1, APOB, NR1H2 | GPR52 972/4885NPC1 48/4885RAB9A 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.